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1. Introduction 
Understanding of human diseases has been enormously expanded by the use of animal 
models, because they allow for in-depth investigation of pathogenesis and provide 
invaluable tools for diagnostic and pharmaceutical purposes. Atopic dermatitis (AD) is a 
chronic, relapsing form of skin inflammation, a disturbance of epidermal-barrier function 
that culminates in dry skin, pruritus, and IgE-mediated sensitization to food and 
environmental allergens (Bieber, 2008, Mori, et al., 2010, Tokura, 2010). AD is a common 
disease with no satisfactory form of therapy; therefore, understanding the mechanism of AD 
through animal models is an urgent issue to be solved (Jin, et al., 2009, Matsuda, et al., 1997, 
Shiohara, et al., 2004). The complexity and variability of AD and multiple genetic and 
environmental factors underlying AD make creating a reproducible, accessible, and relevant 
animal model of AD particularly challenging (Scharschmidt &Segre, 2008). 
Thus far, a number of mouse models have been developed. These models can be categorized 
into three groups: (1) models induced by epicutaneous application of sensitizers; (2) 
transgenic mice that either overexpress or lack selective molecules; and (3) mice that 
spontaneously develop AD-like skin lesions. These models display many features of human 
AD, and their studies have resulted in a better understanding of the pathogenesis of AD. 
They allow for an in-depth dissection of the mediators and cells that are critical for the 
development of allergic responses (Jin, et al., 2009). 
Located at the interface between the body and the environment, the epidermis is an 
elaborate structure that shares few properties with other biological barriers. Key functions 
include providing physical and biochemical protection (O'Regan &Irvine, 2010), and playing 
important roles in host defense, inflammation, and regulation of immune responses 
(Schleimer, et al., 2007). Patients with AD exhibit impaired skin barrier functions and 
abnormal structure and chemistry of the stratum corneum (SC) (Leung &Bieber, 2003). 
Alteration of the skin barrier in AD is evidenced by reduction in the water content of the SC 
and by increased transepidermal water loss (TEWL) (Aioi, et al., 2001). Skin barrier 
dysfunction has emerged as a critical driving force in the initiation and exacerbation of AD 
and as “driver” of disease activity (Cork, et al., 2009, Elias, et al., 2008), although it has once 
been noted as a disease of immunological etiology (Leung &Bieber, 2003). 
Elias et al. proposed the outside-to-inside pathogenic mechanisms in AD for the following 
reasons: (1) the extent of the permeability barrier abnormality parallels the severity of the 
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disease phenotype in AD; (2) both the clinically uninvolved skin sites and the skin cleared of 
inflammation continue to display significant barrier abnormalities; (3) emollient therapy 
comprises effective ancillary therapy; and (4) specific replacement therapy which targets the 
prominent lipid abnormalities that account for barrier abnormality in AD, not only corrects 
the permeability-barrier abnormality but also comprises an effective anti-inflammatory 
therapy for AD (Elias, et al., 2008). 
The evidence for a primary structural abnormality of the SC in AD is derived from a 
recently discovered link between the incidence of AD and loss-of-function mutations in the 
gene encoding filaggrin (FLG). Genetic studies have shown a strong association between AD 
and this mutation (Jin, et al., 2009). Moreover, there is a dose-response relationship between 
FLG deficiency and disease severity, such that patients with double-allele or compound 
heterozygote mutation in FLG display more severe and earlier-onset AD and an increased 
propensity for AD to persist into adulthood (Brown, et al., 2008, Irvine &McLean, 2006). This 
rapidly growing body of work has led to a paradigm shift in conception of AD 
pathogenesis, with increasing weight being placed on the role of a primary barrier 
abnormality that then precipitates downstream causing immunologic abnormalities as 
proposed (Elias, et al., 2008). 
Based on these findings, it is assumed that mice that have a genetic defect in barrier function 
will provide a model of AD closer to the human disease than models provided by epidermal 
sensitization with allergens or haptens or by transgenic overexpression of cytokines in the skin 
or disruption of immune genes, and that these mice will have an advantage over NC/Nga 
mice in which the genetic defect is not known. Application of the knowledge gained from 
existing mouse models of AD to mice with genetic defects in skin barrier function should 
provide us with AD models that closely mimic human disease (Jin, et al., 2009). 
2. Filaggrin and atopic dermatitis 
2.1 Filaggrin mutation and atopic dermatitis 
Filaggrin protein is localized in the granular layers of the epidermis. Profilaggrin, a 400-kDa 
polyprotein, is the main component of keratohyalin granules (Candi, et al., 2005, Listwan & 
Rothnagel, 2004). In the differentiation of keratinocytes, profilaggrin is dephosphorylated 
and cleaved into 10-12 essentially identical 27-kDa filaggrin molecules, which aggregates in 
the keratin cytoskeleton system to form a dense protein-lipid matrix in humans (Candi, et 
al., 2005). This structure is thought to prevent epidermal water loss and impede the entry of 
external stimuli, such as allergens, toxic chemicals, and infectious organisms. Therefore, 
filaggrin is a key protein in the terminal differentiation of the epidermis and in skin-barrier 
function (Gan, et al., 1990). 
The genetic contribution of FLG loss-of-function mutations to AD is now well established. 
FLG mutation was first identified in ichthyosis vulgaris (IV), a common keratinizing 
disorder (Irvine &McLean, 2006). In 2006, Palmer et al. first identified two such mutations 
within the FLG gene, which strongly predispose to AD as well as IV (Palmer, et al., 2006). 
Since then, several additional studies have confirmed this association and discovered other 
mutations within this gene that predispose to AD. To date, approximately 40 loss-of-
function FLG mutations have been identified in IV and/or AD in European and Asian 
populations. (Brown, et al., 2008, Marenholz, et al., 2006, Nomura, et al., 2007, Rodriguez, et 
al., 2009, Sandilands, et al., 2006, Sandilands, et al., 2007). Major differences exist in the 
spectra of FLG mutations observed between different ancestral groups, and each population 
is likely to have a unique set of FLG mutations (Osawa, et al., 2011). 
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Typically atopic manifestations follow a certain sequence, called the atopic march, 
beginning with AD in early infancy, followed by food allergy, asthma and the development 
of allergic rhinitis (Illi, et al., 2004). The association of FLG mutation with atopic march has 
been reported in cases involving pediatric asthma (Muller, et al., 2009), peanut allergy 
(Brown, et al., 2011), atopic asthma (Poninska, et al., 2011), allergic rhinitis (Poninska, et al., 
2011) and nickel allergy (Novak, et al., 2008). 
In addition, epidemiological studies have identified extremely significant statistical 
association between FLG mutation and AD. Intriguingly, these mutations are highly 
associated with several characteristics in AD patients, such as reduced level of natural 
moisturizing factor (NMF) in the SC (Kezic, et al., 2008), increased incidence of dry and 
sensitive skin (Sergeant, et al., 2009), clinical severity and barrier impairment (Nemoto-
Hasebe, et al., 2009), allergen sensitization and subsequent development of asthma 
associated with eczema (Weidinger, et al., 2008), and serum levels of IgE (Wang, et al., 2011). 
On the other hand, several studies failed to identify an effect of FLG mutations on AD, such 
as skin conditions assessed by clinical scoring of AD and measurement of TEWL in a French 
population (Hubiche, et al., 2007). A similar lack of association was reported in contact 
allergy (Carlsen, et al., 2011) and pediatric eczema (O'Regan, et al., 2010).  
As the conceptual framework underlying AD moves from solely immunological to 
epidermal barrier defects, the role of filaggrin and its putative mechanisms in priming AD 
have come under closer scrutiny. FLG mutations are postulated to have wide-ranging 
downstream biological effects, which include altered pH of SC, cutaneous microflora and 
aberrant innate and adaptive immune responses (O'Regan &Irvine, 2010). 
2.2 Filaggrin and altered skin barrier function 
AD is characterized by eczematous skin lesion, dry skin, pruritus, increased TEWL, and 
enhanced percutaneous penetration of both lipophilic and hydrophilic compounds (Jakasa, 
et al., 2011, Wollenberg &Bieber, 2000). The skin barrier defect is one of the primary events 
that initiate disease pathogenesis, allowing the entrance of numerous antigens into the 
epidermis in patients with AD (Onoue, et al., 2009, Osawa, et al., 2011). The FLG mutation 
carriers have demonstrated elevated TEWL (Jungersted, et al., 2010, Kezic, et al., 2008), basal 
erythema, skin hydration, increased skin pH (Jungersted, et al., 2010, Nemoto-Hasebe, et al., 
2009), SC thickness (Nemoto-Hasebe, et al., 2009), impaired SC integrity upon repeated tape 
stripping (Angelova-Fischer, et al., 2011), and increased diffusivity of PEG 370 (Jakasa, et al., 
2011) compared to healthy donors. Nevertheless, these alterations found in FLG mutation 
carriers are not consistently correlated with AD since AD patients without FLG mutation 
might also share some similar features. (Hubiche, et al., 2007, Jakasa, et al., 2011, Jungersted, 
et al., 2010, Kezic, et al., 2008). It is, therefore, suggested that other factors besides FLG loss-
of-function mutations modulate skin barrier integrity, especially in AD. 
Since the skin barrier is related to intercellular lipid bilayers of the SC, it might be interesting to 
examine the composition and the organization of intercellular lipids of the SC in AD patients 
in relation to FLG genotype and disease severity (Jakasa, et al., 2011). Carriers of FLG 
mutations showed significantly reduced levels of NMF in the SC (Kezic, et al., 2008). Similar 
lipid composition of FLG mutation carriers and individuals with normal filaggrin was 
observed (Angelova-Fischer, et al., 2011, Jungersted, et al., 2010), but a lower 
cermide/cholesterol ratio was detected in the former group (Angelova-Fischer, et al., 2011). 
Filaggrins proteolytically degraded into a pool of free amino acids including histidine and 
glutamine which are further converted to, respectively, urocanic acid (UCA) and 2-
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pyrrolidone-5-carboxylic acid (PCA). The concentrations of UCA and PCA in SC in the carriers 
of FLG mutations were significantly lower than those in healthy donors (Kezic, et al., 2009). 
Therefore, filaggrin deficiency is sufficient to impair epidermal barrier formation. 
An in vitro experiment using filaggrin knocked down human organotypic skin cultures 
showed enhanced penetration of hydrophilic dye Lucifer yellow, smaller lamellar bodies, and 
deficiency of their typical lamellae without altered lipid composition (Mildner, et al., 2010). In 
addition, UCA, one of the filaggrin-derived free amino acids and as an important UV 
absorbent within SC, was decreased following filaggrin knocked down, leading to increased 
sensitivity to UVB-induced keratinocyte (KC) damage (Mildner, et al., 2010). 
2.3 Filaggrin and altered immunobiology 
The SC serves as a biosensor of the external environment and a link between innate and 
adaptive immune systems (Vroling, et al., 2008). The critical association between the 
abnormal barrier in AD and Th2 polarization may in part be explained by the production of 
the cytokine, thymic stromal lymphopoietin (TSLP) (Ebner, et al., 2007). TSLP is expressed 
by epithelial cells, with the highest levels seen in lung-derived and skin-derived epithelial 
cells (Soumelis, et al., 2002, Ziegler, 2010), and is highly detected in the lesional skin of AD 
(Soumelis, et al., 2002) Inducible TSLP transgene specifically in the skin leads to the 
development of a spontaneous Th2-type skin inflammatory disease with the hallmark 
features of AD (Yoo, et al., 2005). 
TSLP has been shown to activate dendritic cells to drive Th2 polarization, through 
upregulation of the co-stimulatory molecules CD40, CD80, and OX40L, triggering the 
differentiation of allergen-specific naïve CD4+ T cells to Th2 cells that produce IL-4, IL-5, 
and IL-13 (Ebner, et al., 2007, Soumelis, et al., 2002). 
Patients with Netherton syndrome (NS), a severe ichthyosis in which affected individuals 
experience a significant predisposition for AD, have elevated levels of TSLP in their skin. 
Upregulated kallikrein (KLK) 5 in the skin of NS patients directly activates proteinase-
activated receptor 2 (PAR-2) and induces nuclear factor kappaB-mediated overexpression of 
TSLP, intercellular adhesion molecule 1, TNF-α, and IL-8. This phenomenon occurs 
independently of the environment, adaptive immune system and underlying epithelial 
barrier defect (Briot, et al., 2009, Briot, et al., 2010). In vitro study using human keratinocyte 
cell line HaCaT cells and reconstituted human epidermal layers transfected with filaggrin 
siRNA showed increased production of TSLP via toll-like receptor (TLR) 3 stimulation (Lee, 
et al., 2011). These findings suggest that reduced filaggrin levels may influence innate 
immune response via TLR stimuli and elevate TSLP, leading to AD-like skin lesions. 
AD is one of the emerging diseases in which epidermal dysfunction increases allergen and 
microbial penetration in the skin, with the consequent development of adaptive Th2 
immune responses (Kondo, et al., 1998) within regional lymphoid tissue. The resultant Th2 
cells may then home back to the skin or lungs, where they recognize allergen in the skin 
(McPherson, et al., 2010), which leads to local Th2 inflammation, reduced antimicrobial 
peptide expression (Nomura, et al., 2003), and filaggrin downregulation (Howell, et al., 
2007). Indeed, the induction of circulating allergen-specific CD4+ T cells may be an 
important prerequisite underlying the pathogenesis of the atopic march (O'Regan, et al., 
2009). Among moderate-to-severe AD patients, the FLG mutation carriers showed a greater 
number of house dust mite Der p1-specific IL-4 producing CD4+ T cells, suggesting that 
filaggrin mutations predispose to the development of allergen-specific CD4+ Th2 cells. The 
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same result could be seen among HLA-DRB1*1501 (a HLA class II complex which is 
immunodominant in individuals with AD (Ardern-Jones, et al., 2007)) positive adult 
individuals with moderate-to-severe AD and FLG mutations (McPherson, et al., 2010). 
3. Flaky tail mouse as a novel animal model of atopic dermatitis 
3.1 Origin of flaky tail mice 
The above findings indicate the involvement of filaggrin in the development of AD. 
Therefore, the impact of filaggrin deficiency on cutaneous biological functions in vivo should 
be analyzed in detail. To address this issue, animal models are of great value. 
Flaky tail mice (Flgft), first introduced in 1958, are spontaneously mutated mice with smaller 
ears, tail constrictions, and a flaking tail skin appearance (Lane, 1972). Flgft mice were 
outcrossed onto B6 mice at Jackson Laboratory (Bar Harbor, ME, USA) (Lane, 1972, 
Presland, et al., 2000) (Note: Although this strain was crossed with B6, it is not a B6 congenic 
strain but rather a hybrid stock that is probably semi-inbred). Homozygous Flgft mice have 
dry, flaky skin which expresses reduced amounts of profilaggrin mRNA and abnormal 
profilaggrin protein that is not processed to filaggrin monomers (Fallon, et al., 2009, 
Presland, et al., 2000). 
Recently, it has been revealed that the gene responsible for the characteristic phenotype of 
Flgft mice is a single nucleotide deletion at position 5303 in exon 3 (5303delA) of the 
profilaggrin gene, resulting in a frameshift mutation and premature truncation of the 
predicted protein product. The copy number of the filaggrin repeat contained within this 
gene varies depending on the background strain. This mutant occurs in an allele with 16 
copies of the filaggrin repeat (Fallon, et al., 2009). 
Flgft mouse carries double gene mutation, Flg and matted (ma) in which the locations of the 
mutated genes are within close linkage to one another (Lane, 1972). The ma gene 
characteristic reported by Searle & Spearman (1957) causes the body-hair of affected mice to 
be brittle and inflexible, which results in longitudinal splitting and breaking due to friction 
against the cage and other objects. This mutation is a fully penetrant recessive house-mouse 
mutant which belongs to the “naked” category (i.e., a house-mouse with baldness resulting 
from the breaking of hairs or from hereditary hairlessness). This mutation can be identified 
morphologically by (1) erection of hairs, (2) matting of hair in clumps, (3) a tendency 
towards baldness, (4) a change from black- to brown-colored melanin in old hairs. The age 
at which this mutant is first identified based on external appearance varies from between 
two to four weeks (Jarret A, 1957, Searle A.G., 1957). 
Recognition of the features of this mouse is more evident between 5 and 14 days of age 
when constricted, flaking tail skin and thickened short pinna of the ears are observed. In 
addition, Flgft mice are often smaller than their normal siblings at this age. Routine 
histological sections stained with hematoxylin and eosin showed that the stratum 
granulosum in Flgft mice at 1, 2, 4, and 8 days of age does not contain as many granular 
layers as that of non-Flgft mice (Lane, 1972). Mice of the Flgft genotype express an abnormal 
profilaggrin polypeptide that does not form normal keratohyalin F-granules and is not 
proteolytically processed to filaggrin. Therefore, filaggrin is absent from the cornified layers 
in the epidermis of the Flgft mouse (Fallon, et al., 2009, Presland, et al., 2000, Scharschmidt, et 
al., 2009). Consistently, we and others have described that Flgft mice express a truncated and 
smaller profilaggrin protein that is not processed to filaggrin (Fallon, et al., 2009, Moniaga, 
et al., 2010, Presland, et al., 2000) (Fig.1). 
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Fig. 1. Flgft mouse has a truncated and smaller profilaggin and a lack of filaggrin protein. 
3.2 Flaky tail mouse and ichtyosis vulgaris 
Ichthyosis vulgaris (IV) is a heterogeneous autosomal skin disease characterized by dry and 
scaly skin, mild hyperkeratosis, and a decreased or absent granular layer that either lacks, or 
contains morphologically abnormal, keratohyalin granules (Manabe, et al., 1991). Several 
lines of evidences point to a genetic defect in a gene encoding FLG in IV. Immunoblotting 
studies showed that filaggrin protein was absent or markedly reduced in the epidermis of 
individuals with IV (Fleckman, et al., 1987, Sybert, et al., 1985). In line with this, it was 
proposed that Flgft mice could provide insight into the molecular basis of the filaggrin-
deficient human skin disorder IV. The epithelia of Flgft mice showed defects in tissue 
organization especially in the tail, an attenuated granular layer, reduced profilaggrin and a 
lacked of filaggrin granules in SC. In addition, keratinocytes culture from Flgft mice 
synthesized reduced amounts of profilaggrin mRNA and protein (Presland, et al., 2000). 
3.3 Flaky tail mouse in a steady state 
An early report demonstrated that Flgft mice without the ma mutation showed flaky skin as 
early as postnatal day 2, but became normal in appearance by 3 to 4 weeks of age without 
spontaneous dermatitis except for their slightly smaller ears (Lane, 1972). Later, the lack of 
filaggrin in the epidermis was proposed in the commercially available strain of Flgft mice, 
which has both Flg and ma mutations, as a model of IV, and therefore there was no 
discussion about the cutaneous inflammatory conditions from the perspective of AD 
(Presland, et al., 2000). 
There have been four recent papers of Flgft mice as a model of filaggrin deficiency: the first 
paper used Flgft mice from which the ma mutation had been eliminated with four additional 
backcrosses to B6 mice (Fallon, et al., 2009), and the others used the commercially available 
Flgft mice (Moniaga, et al., 2010, Oyoshi, et al., 2009, Scharschmidt, et al., 2009). The first 
report showed only histological abnormality without clinical manifestation (Fallon, et al., 
2009), and the second demonstrated spontaneous eczematous skin lesions after 28 weeks of 
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age (Oyoshi, et al., 2009), and the third contained no notice of any spontaneous dermatitis in 
Flgft mice (Scharschmidt, et al., 2009). 
The fourth paper by Moniaga et al. have demonstrated that Flgft mice showed spontaneous 
dermatitis with skin lesions mimicking human AD as early as 5 weeks of age with mild 
erythema and fine scales and the cutaneous manifestations advanced with age in a steady 
state under SPF conditions (Moniaga, et al., 2010) (Fig. 2). The first manifestations to appear 
when mice were young were erythema and fine scaling; pruritic activity, erosion, and edema 
followed later (Fig. 3). In contrast, no cutaneous manifestation was observed in either C57BL/6 
mice, studied as a control, or heterozygous mice intercrossed with Flgft and B6 mice kept under 
SPF conditions. There was no apparent difference in terms of clinical manifestations based on 
the gender of Flgft mice throughout the period (Moniaga, et al., 2010). 
 
 
Fig. 2. Clinical photographs of 20-week-old Flgft mice (left panel) and total clinical severity 
scores (right panel) 
 
 
Fig. 3. Characteristics of the clinical skin lesions. 
Histological examination of the skin of Flgft mice stained with H&E revealed epidermal 
acanthosis, increased lymphocyte and mast cell infiltration and dense fibrous bundles in the 
dermis, in both younger (8-week-old) and older (18-week-old) Flgft mice; none of these 
conditions were observed in B6 mice (Fig. 4) (Moniaga, et al., 2010). These features were also 
reported in other studies (Fallon, et al., 2009, Oyoshi, et al., 2009) with more total cells, 
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lymphocytes, eosinophils, and mononuclear cells in Flgft mice compared to control mice. 
These data support the diagnosis of AD-like dermatitis in Flgft mice in the steady state under 
SPF conditions. 
 
 
Fig. 4. Hematoxyllin and eosin (H&E)-stained sections in 8- and 18-week old mice. Scale 
bar, 100µm 
Therefore, there exist discrepancies among the results of four recent papers on the 
cutaneous manifestation in the steady states. It seems to be related to the presence or 
absence of the ma mutation and/or variation in the genetic backgrounds of the different 
strains used, and to environmental factor. It has been reported that Japan carries a higher 
morbidity of AD than other countries (1998, Williams, et al., 1999), possibly due to 
environmental factors such as pollen. Because barrier dysfunction is a common 
characteristic of AD (Elias, et al., 2008, Nomura, et al., 2007, Palmer, et al., 2006), TEWL is 
commonly measured as an indicator of barrier function (Gupta, et al., 2008). TEWL was 
significantly higher in Flgft mice than in B6 mice from an early age (4 weeks) to an older 
age (16 weeks) (Fig. 5) (Moniaga, et al., 2010). 
 
 
Fig. 5. TEWL through dorsal skin of 5-, 8-, and 16-week-old B6 and Flgft mice. 
Flowcytometry analysis of cells isolated from ear skin confirmed that Flgft skin contained 
significantly increased percentages of CD4+ T cells and Gr-1+ neutrophils, but not CD11c+ 
dendritic cells, compared with ear skin from controls (Moniaga, et al., 2010, Oyoshi, et al., 2009). 
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The extent of severity of AD is known to be correlated with elevated serum IgE levels 
(Novak, 2009). Serum IgE and IgG1 levels in Flgft mice were significantly higher than 
those in control mice in the steady state under SPF conditions (Moniaga, et al., 2010, 
Oyoshi, et al., 2009). In addition, the numbers of CD4+ and CD8+ cells in the skin draining 
LNs in Flgft mice were significantly higher than those in control mice, but those of the 
spleen were similar for both groups. Thus, an enhanced cutaneous immune reaction 
seems to be induced in Flgft mice due to the condition of their skin induced by filaggrin 
and/or matted deficiency. 
AD is thought to be mediated by helper T cell subsets, such as Th1, Th2, and Th17 
(Bieber, 2008, Hattori, et al., 2010, Koga, et al., 2008). In the steady state, the skin of Flgft 
mice showed no difference of Th1 cytokine IFN-γ and Th2 cytokines IL-4 and IL-13 
compared to the control. In contrast, there is a significant increase in mRNA expression 
of the Th17 cytokine IL-17, IL-17 promoting cytokines IL-6 and IL-23 (p19), and IL-17 
inducible neutrophil attractant chemokine CXCL2 in Flgft mice (Moniaga, et al., 2010, 
Oyoshi, et al., 2009). 
3.4 Flaky tail mouse showed enhanced percutaneous allergen priming 
Since the barrier dysfunction is a key element in the establishment of AD, it is necessary to 
evaluate outside-to-inside barrier function from the perspective of invasion of external 
stimuli. Scharschmidt et al. reported increased bidirectional paracellular permeability of 
water-soluble xenobiotes by ultrastructural visualization in Flgft mice suggesting a defect 
in the outside-to-inside barrier. The ultrastructural visualization of tracer perfusion was 
analyzed by water-soluble, low molecular weight, electron-dense tracer lanthanum nitrate 
or fluorophore calcium green with enhanced penetration in Flgft mice. The data 
demonstrated that filaggrin deficiency leads to alterations in basal barrier function 
through a defect in the SC extracellular matrix and greater permeability through the same 
paracellular pathway that is used by water itself when exiting the skin (Scharschmidt, et 
al., 2009). 
A new method for evaluating outside-to-inside barrier function quantitatively by measuring 
the penetrance of fluorescein isothiocyanate isomer 1 (FITC) through the skin has been 
developed (Moniaga, et al., 2010). The epidermis of Flgft mice contained a higher amount of 
FITC than that of B6 mice did (Fig.6 left panel). Consistently, fluorescence intensities 
observation in the epidermis of both mice showed stronger fluorescence in Flgft mice (Fig.6 
right panel). In addition, the Flgft embryo was entirely dye permeable to toluidine blue 
solution compared to its control littermate. 
Another AD-like dermatitis model to test allergen priming of the skin in these mice was 
performed by application of ovalbumin (OVA) (Oyoshi, et al., 2009). Non tape-stripped 
skin of Flgft mice exposed to OVA exhibited significantly increased epidermal thickening, 
hyperkeratosis, spongiosis, acanthosis, and cellular infiltrates, as well as TEWL compared 
to control mice. mRNA levels for IL-17, IL-6, IL-23, IL-4, IFN-γ and CXCL2 but not IL-5 
and IL-13 in the skin of Flgft mice after OVA exposure were significantly higher than those 
of control mice. The systemic immune response following cutaneous exposure revealed 
increased specific IgG and IgE to OVA, and splenocytes proliferated and produced OVA-
specific Th1, Th2, Th17 and regulatory T cell cytokines (Fallon, et al., 2009, Oyoshi, et al., 
2009). These findings demonstrate that Flgft mice tend to generate allergen-specific IgE 
and cytokine following cutaneous allergen challenge to the skin even without additional 
barrier disruption. 
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Fig. 6. Amount of FITC in the skin of B6 and Flgft mice (left panel) and fluorescence 
intensities of FITC of the skin (right panel) after topical application. 
3.5 Altered immunobiology response in flaky tail mouse 
The skin abnormality associated with AD is well known to be a predisposing factor to 
sensitive skin (Farage, et al., 2006, Willis, et al., 2001) and allergic contact dermatitis 
(Clayton, et al., 2006, Mailhol, et al., 2009). However, children with atopic dermatitis had 
lower PPD induration size compared to healthy donors, but this was not statistically 
significant (Gruber, et al., 2001, Yilmaz, et al., 2000). In humans, sensitive skin is defined as 
reduced tolerance to cutaneous stimulation, with symptoms ranging from visible signs of 
irritation to subjective neurosensory discomfort (Farage, et al., 2006, Willis, et al., 2001). The 
question of whether human AD patients are more prone to allergic contact dermatitis than 
nonatopic individuals is still controversial (Mailhol, et al., 2009). 
Using phorbol myristate acetate (PMA) as an irritant, Flgft mice exhibited an enhanced ear 
swelling response compared to age-matched B6 mice throughout the experimental period (1 
hr to 140 hrs). In addition, Flgft mice showed an increased skin-sensitized contact 
hypersensitivity (CHS) reaction to hapten, a form of classic Th1- and Tc1-mediated delayed-
type hypersensitivity to haptens, emphasized by increased IFN-γ production, and 
terminated by regulatory T cells (Honda, et al., 2010, Mori, et al., 2008, Wang, et al., 2001). 
CHS is induced by epicutaneous sensitization and challenge. The ear thickness change was 
more prominent in Flgft mice than in B6 mice. In addition, the relative amount of IFN-γ in 
the ear of Flgft mice was higher than that of B6 mice. 
To further assess the immune responses of Flgft mice, we elicited a delayed-type 
hypersensitivity (DTH) response through non-epicutaneous sensitization and challenge. 
Mice were immunized intraperitoneally with OVA, and challenged with a subcutaneous 
injection of OVA into the footpad. In contrast to the CHS response induced epicutaneously, 
the resulting footpad swelling in Flgft mice tended to be lower than that in wild-type mice. 
This finding is consistent with the observation on tuberculin tests in human. The levels of 
IFN-γ in the spleen were comparable between Flgft mice and wild-type mice. Thus, Th1/Tc1 
immune responses were enhanced in Flgft mice only when the stimuli operated via the skin, 
suggesting that the enhanced immune responses seen in Flgft mice depend on skin barrier 
dysfunction and skin barrier function regulates cutaneous immune conditions, which hints 
at a possible mechanism involved in human AD. 
A reduced threshold in Flgft mice for contact dermatitis was also reported. These mice 
showed enhanced propensity to irritant contact dermatitis via low-dose phorbol ester TPA 
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which provokes only marginal inflammation in wild-type mice, and displayed a reduced 
threshold for the development of hapten-induced acute allergic contact dermatitis by 
oxazolone (Ox). Repeated Ox challenges with lower doses of Ox revealed AD-like dermatitis 
in Flgft mice as shown by severe barrier abnormality (enhanced TEWL) and AD-like 
histological changes (Scharschmidt, et al., 2009). 
3.6 Flaky tail mouse denotes human AD 
Clinical studies have provided evidence that a house dust mite allergen plays a causative or 
exacerbating role in human AD (Kimura, et al., 1998), and that a strong correlation exists 
between FLG mutation patients and house dust mite-specific IgE (Henderson, et al., 2008). 
Dermatophagoides pteronyssinus (Dp) is a common mite aeroallergen, which is frequently 
involved in inducing human AD. Dp exhibits protease activities, and Der p1, Der p3, and 
Der p9, derived from Dp, are especially capable of activating the PAR-2 in human KC 
(Jeong, et al., 2008, Vasilopoulos, et al., 2007). A recent report has shown that activation of 
PAR-2 through Dp application significantly delays barrier recovery rate in barrier function-
perturbed skin or otherwise compromised skin (Jeong, et al., 2008). Therefore, Dp may play 
a dual role in the onset of AD, both as an allergen and proteolytic signal and as a 
perturbation factor of the barrier function, leading to the persistence of eczematous skin 
lesions in AD (Jeong, et al., 2008, Roelandt, et al., 2008). It has also been reported that 
BALB/c and NC/Nga mice develop an allergic cutaneous immune response to mite 
antigens when they are applied to the skin after vigorous barrier disruption by means of 
tape-stripping or sodium dodecyl sulfate treatment (Kang, et al., 2006, Yamamoto, et al., 
2007). Intriguingly, the application of Dp ointment to the skin without additional barrier 
disrupt induced dermatitis in Flgft mice, while this treatment did not induce any skin 
inflammation in control C57BL/6 mice (Fig.7). Petrolatum alone, used instead of Dp 
ointment as a control, induced no skin manifestation (Fig. 7). 
 
 
Fig. 7. The mite-induced dermatitis model showed severe eczematous skin lesion after being 
topically treated with Dp ointment in Flgft mice, as well as ear thickness change.  
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Histological examination of H&E-stained sections of involved Flgft skin after 16 
applications showed acanthosis, elongation of rete ridges, and dense lymphocyte and 
neutrophil infiltration in the dermis, accompanied by an increased number of mast cells in 
the dermis. Consistently, scratching behavior, TEWL, and Dp-specific IgE levels were 
significantly higher in Flgft mice than in B6 mice (Fig.8) (Moniaga, et al., 2010). Thus the 
treatment of Flgft mice with Dp ointment, even without prior barrier disruption, 
remarkably enhanced both the clinical manifestations and the laboratory findings that 
correspond to indicators of human AD. 
 
 
Fig. 8. TEWL and mite-specific serum IgE levels of Flgft mice and control mice after the last 
application. 
4. Summary and future direction 
We have summarized the findings on Flgft mice revealed by four different groups (Table 1). 
While most of these findings were consistent with each other, there still remain several 
issues to be solved, for example, the influence of the genetic background and other gene 
mutations in these mice. 
 
 Fallon  
et al. 
(Fallon, et al., 
2009)
Oyoshi  
et al. 
(Oyoshi, et al., 
2009)
Scharschmidt 
et al. 
(Scharschmidt,  
et al., 2009)
Moniaga  
et al.  
(Moniaga, et al., 
2010) 
Spontaneous AD - + n.r. + 
Increased TEWL in steady 
state 
slightly n.r. + (old age) + 
Histopathology AD like 
skin lesion in steady state
+ + n.r. + 
Increase total IgE in steady 
state 
n.r. + + + 
Enhanced cutaneous 
antigen ingress 
+ (OVA) + (OVA) 
+ (low dose 
oxaxolone) 
+ (mite, 
D.p.) 
Enhanced non cutaneous 
antigen (OVA-i.p) 
response 
- - n.r - 
Table 1. Summary of the phenotypes of flaky tail mice 
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Since Flgft mice are not a homogenous C57BL/6 background, two papers with 
spontaneous eczematous skin lesion on Flgft mice compared their outcomes with other 
mouse strains, such as C57BL6 and BALB/c mice as controls (Oyoshi, et al., 2009); these 
two strains lie on opposite ends of the spectrum of T helper responses. Nevertheless, the 
skin inflammation and susceptibility to EC sensitization of non-tape stripped skin 
observed in Flgft mice were not observed in other strains. In the second paper, they 
observed immune responses in mice of other genotypes, such as BALB/c and C3H, as 
controls, but both of these lines exhibited much less severe CHS responses compared to 
Flgft mice (Moniaga, et al., 2010). These data suggested that the enhanced responses seen 
in Flgft mice were not solely due to their genetic background. In addition, other studies 
used the Flgft mice which were backcrossed four generations to a B6 strain (a background 
coding sequence showed 99.3% identity between B6 and Flgft), and similar enhanced 
responses to OVA-induced AD models were observed (Fallon, et al., 2009). 
Furthermore, unlike human AD patients, most of whom are heterozygous for the FLG 
mutation, the heterozygous mice intercrossed with Flgft mice and B6 mice did not develop 
spontaneous dermatitis (Moniaga, et al., 2010). Similar results were obtained with the 
OVA-induced AD model, where homozygous, but not heterozygous (crossed with B6 
mice) Flgft mice, showed enhanced susceptibility to cutaneous exposure to OVA (Fallon, et 
al., 2009). Not only human studies but also additional mouse studies will be required to 
clarify these relationships. 
Since Flgft mice express a hair phenotype (matted), one cannot eliminate the possibility 
that some of the observations could have been influenced by the concurrent ma mutation 
(Scharschmidt, et al., 2009). Nevertheless, one study indeed removed the matted hair 
allele (ma) early in the course of backcrossing with B6 mice, and showed enhanced antigen 
(OVA) ingress in mice with the same Flg mutation, but no ma mutation in their 
background (Fallon, et al., 2009). The effect of the ma mutation in relation to the Flg 
mutation in commercially available Flgft mice in the development of AD-like skin lesions 
needs to be clarified in future studies. 
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pathophysiology of Atopic Dermatitis is discussed in the second section (Microorganisms in Atopic Dermatitis).
An overview of the clinical diagnostic criteria and the disease management protocols commonly used is given
in the third section (Diagnosis and Clinical Management). The last section (New Treatments) describes new
therapeutic approaches that are not widely used but are currently being studied due to preliminary evidence
showing a clinical benefit for Atopic Dermatitis.
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